No Data
No Data
No Data
No Data
No Data
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
TipRanksApr 8 12:10 ET
Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Facts
RTTNewsApr 8 09:08 ET
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib,
GlobeNewswireApr 8 08:30 ET
Insider Buys Additional US$51k In Nuvectis Pharma Stock
Yahoo FinanceMar 21 06:08 ET
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$51,450 in Common Stocks
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 5,000 shares of Common Stocks on Mar 18, 2024 at an average price of $10.29 for a total value of $51,450.Source: Announcement What is s
moomoo NewsMar 19 08:39 ET
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati
GlobeNewswireMar 19 08:00 ET
No Data
No Data